Prediction and Modeling of Effects on the QTc Interval for Clinical Safety Margin Assessment, Based on Single-Ascending-Dose Study Data with AZD3839-Reference-Cited by-同舟云学术

Prediction and Modeling of Effects on the QTc Interval for Clinical Safety Margin Assessment, Based on Single-Ascending-Dose Study Data with AZD3839

Published:2014-06-10 Issue:2 Volume:350 Page:469-478
ISSN:0022-3565
Container-title:Journal of Pharmacology and Experimental Therapeutics
language:en
Short-container-title:J Pharmacol Exp Ther

Author:

Sparve Erik,Quartino Angelica L.,Lüttgen Maria,Tunblad Karin,Gårdlund Anna Teiling,Fälting Johanna,Alexander Robert,Kågström Jens,Sjödin Linnea,Bulgak Alexander,Al-Saffar Ahmad,Bridgland-Taylor Matthew,Pollard Chris,Swedberg Michael D. B.,Vik Torbjörn,Paulsson Björn

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmacology,Molecular Medicine

Reference26 articles.

1. Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models

2. Optimisation and validation of a medium-throughput electrophysiology-based hERG assay using IonWorks™ HT

3. Drugs that prolong QT interval as an unwanted effect: assessing their likelihood of inducing hazardous cardiac dysrhythmias

4. Food and Drug Administration (2005) Guidance for Industry, E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs, US Department of Health and Human Services, FDA, Center for Drug Evaluation and Research, Silver Spring, MD.

5. Fridericia LS (1920) The duration of systole in the electrocardiogram of normal subjects and of patients with heart disease. Acta Med Scand 53:469–486.

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Small-molecule BACE1 inhibitors: a patent literature review (2011 to 2020);Expert Opinion on Therapeutic Patents;2020-12-17

2. Safety, Tolerability, Pharmacokinetics, Target Occupancy, and Concentration‐QT Analysis of the Novel BTK Inhibitor Evobrutinib in Healthy Volunteers;Clinical and Translational Science;2019-11-29

3. Assessing QT/QTc interval prolongation with concentration-QT modeling for Phase I studies: impact of computational platforms, model structures and confidence interval calculation methods;Journal of Pharmacokinetics and Pharmacodynamics;2018-03-19

4. Clinical Bioavailability of the Novel BACE1 Inhibitor Lanabecestat (AZD3293): Assessment of Tablet Formulations Versus an Oral Solution and the Impact of Gastric pH on Pharmacokinetics;Clinical Pharmacology in Drug Development;2018-01-10

5. Application of a systems pharmacology model for translational prediction of hERG ‐mediated QT c prolongation;Pharmacology Research & Perspectives;2016-11-17